Assenagon Asset Management S.A. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Assenagon Asset Management S.A. raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 171.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 481,389 shares of the biopharmaceutical company's stock after buying an additional 303,785 shares during the quarter. Regeneron Pharmaceuticals comprises about 0.5% of Assenagon Asset Management S.A.'s portfolio, making the stock its 25th biggest holding. Assenagon Asset Management S.A. owned about 0.44% of Regeneron Pharmaceuticals worth $305,311,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of REGN. Capital International Investors lifted its position in Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after buying an additional 1,390,534 shares during the last quarter. Norges Bank purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $802,036,000. GAMMA Investing LLC increased its stake in Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after purchasing an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after purchasing an additional 810,144 shares during the period. Finally, Amundi increased its stake in Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded up $7.40 during midday trading on Friday, reaching $529.24. The company's stock had a trading volume of 951,512 shares, compared to its average volume of 879,349. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock's 50 day simple moving average is $563.19 and its 200 day simple moving average is $649.98. The firm has a market capitalization of $57.14 billion, a PE ratio of 13.83, a P/E/G ratio of 2.34 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period last year, the business posted $9.55 EPS. Regeneron Pharmaceuticals's revenue was down 3.7% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of recent research reports. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. UBS Group cut their price target on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research note on Thursday, June 5th. Royal Bank of Canada lowered shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price target on the stock. in a research note on Friday, May 30th. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research note on Monday, June 2nd. Finally, Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $836.48.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.